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Abstract The performance of the Xpert MRSA polymerase
chain reaction (PCR) assay on pooled nose, groin, and throat
swabs (three nylon flocked eSwabs into one tube) was
compared to culture by analyzing 5,546 samples. The sen-
sitivity [0.78, 95 % confidence interval (CI) 0.73–0.82] and
specificity (0.99, 95 % CI 0.98–0.99) were similar to the
results from published studies on separated nose or other
specimens. Thus, the performance of the Xpert MRSA assay
was not affected by pooling the three specimens into one
assay, allowing a higher detection rate without increasing
laboratory costs, as compared to nose samples alone.
Introduction
The rapid and accurate detection of methicillin-resistant
Staphylococcus aureus (MRSA) carriers helps to reduce
the risk of transmission to other patients. Rapid polymerase
chain reaction (PCR)-based methods enable to confirm or
refute MRSA carriage in patients within 2 h. Most of them
were evaluated with nose specimens, whereas studies
showed that multiple site sampling increases the sensitivity
of MRSA detection [1–6].
The high price of commercially available rapid PCR tests
for MRSA screening leads some laboratories to pool speci-
mens of the same patient into one single assay [7], whereas
others consider that these tests are not cost-effective [8].
Some studies addressed the effect of pooling nose and groin
samples on tests’ performances [9, 10]. As both throat and
groin are additional important sites for MRSA detection [1,
5, 6], validation of the Xpert MRSA assay (Cepheid,
Sunnyvale, CA, USA) carried out on these three swabs
was required. Most of these studies were done using the
Cepheid collection device (Venturi Transystem; Copan,
Brescia, Italy). The new eSwab device (Copan) is increas-
ingly used because it is suitable for the automated inocula-
tion of agar plates, and is more sensitive to recovering
bacteria by culture, including MRSA screening [11–13].
Therefore, we aimed to assess the performance [sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPP)] of the Xpert MRSA assay on pooled
nose, throat, and groin specimens using eSwabs and culture
as the gold standard.
Materials and methods
Screening samples (nose, groin, and throat) were performed
using the eSwab MRSA system (Copan). This collecting
device is composed of a screw-cap tube filled with 1 ml of
Amies liquid and three swabs with flocked nylon fiber tips.
Xpert MRSA tests were performed according to the manu-
facturer’s instructions, except that 100 μL of the Amies
liquid were used to perform the analysis. For culture, about
250 μl of the Amies liquid were inoculated into m-
Staphylococcus broth (Difco, Basel, Switzerland) and incu-
bated overnight at 35 °C. The broth was then inoculated
onto chromogenic MRSA-Select agar (Bio-Rad, Marnes-la-
Coquette, France) and incubated overnight at 35 °C [14].
The DNase and agglutination (Slidex Staph Plus;
bioMérieux, Marcy-l’Etoile, France) tests were performed
to confirm the identification of S. aureus. Susceptibility to
oxacillin was determined by the cefoxitin disk diffusion
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method according to the Clinical and Laboratory Standards
Institute (CLSI) recommendations [15]. The sensitivity,
specificity, PPV, and NPV of the Xpert MRSA assay, and
their 95 % confidence intervals (CIs), were calculated using
the online calculator at http://faculty.vassar.edu/lowry/
clin1.html.
Results
To assess the effect of pooling samples on rapid MRSA
detection, we performed a preliminary investigation. Nose,
groin, and throat sites of 50 known MRSA carriers were first
swabbed with separate eSwab devices (three swabs in three
separated tubes) and then with the eSwab MRSA system
(three swabs in one tube). Each specimen (tube) was ana-
lyzed by the Xpert MRSA assay and culture. In addition,
150 μl of nose, groin, and throat separate samples were
pooled at the laboratory before analysis. With the Xpert
MRSA test, separate analyses of the nose, throat, and groin
yielded a total of 38 (76 %) positive patients (Table 1),
whereas when specimens were pooled, either by the nurses
or at the laboratory, 34 (68 %) and 35 (70 %) patients were
positive, respectively. Similar results were obtained with
culture (Table 1). Thus, a loss in sensitivity of only 6 %
could be attributed to pooling. This reduction is largely
compensated by the benefit of adding throat and groin
samples, which, overall, increases the detection from 52 %
and 54 % to 76 % and 78 % for the Xpert MRSA test and
culture, respectively (Table 1). These results are similar to
the data reported in a larger study [1]. The sensitivities of the
Xpert MRSA assay compared to culture as the gold standard
were not significantly different regarding the site of sam-
pling or the pooling protocol (harvested in one tube by
nurses or pooled at the laboratory) (Table 1) and were
similar to the 86 % sensitivity (95 % CI 0.81–0.91) reported
by the manufacturer. Thus, we chose the eSwab MRSA
system (three swabs in one tube) for a larger evaluation.
From July 2011 to May 2012, 5,555 pooled samples (nose,
groin, and throat) from 3,774 patients were analyzed by both
the Xpert MRSA assay and culture. Only nine samples
(0.16 %) showed invalid results after being tested twice by
the Xpert MRSA assay, and were excluded from the analysis.
Among the 5,546 remaining samples, 297 (5.4 %) were pos-
itive by the Xpert MRSA test and 294 (5.3 %) by culture.
Considering culture as the gold standard, we observed a total
of 65 false-negative and 68 false-positive results. Thus, the
sensitivity of the Xpert MRSA assay was 0.78 (95 % CI 0.72–
0.82), the specificity 0.99 (95 % CI 0.98–0.99), the PPV 0.77
(95 % CI 0.72–0.82), and the NPV 0.99 (95 % CI 0.98–0.99).
These results are similar to previously reported studies on the
Xpert MRSA assay [7, 10, 16–21].
Discussion
Whether the Xpert MRSA test is adequate for detecting
MRSA carriers is an important question. Among the 335
new MRSA carriers identified during this period, 37 (11 %)
would have been missed if culture would not have been
performed, a ratio similar to a previous report [22]. There
are several reasons for that. Some studies report the failure
of the Xpert MRSA assay to detect strains harboring
SCCmec variants [20, 23] or the newly described mecC
[24]. In our study, among the 65 false-negative results, 45
isolates were tested by the Xpert MRSA/SA nasal test
(PCRs for mecA and SCCmec—chromosome junction)
and were positive (data not shown). Moreover, at least 50
(77 %) were due to MRSA strains belonging to four pre-
dominant clones in our area (data not shown), which are
usually correctly identified by the Xpert MRSA assay
(ST45-IV, ST5-II, ST228-I, and ST8-VI; [25]). This indi-
cates that the majority of false-negative results were not due
to SCCmec variants. Another explanation could be the low-
er performance of the Xpert MRSA assay compared to
culture. This hypothesis is supported by a study reporting
Table 1 Number of positive results and sensitivity of the Xpert MRSA assay compared to culture on pooled or nonpooled samples of the nose,
groin, and throat among 50 known methicillin-resistant Staphylococcus aureus (MRSA) carriers
No. of positives
by Xpert MRSA
No. of positives
by culture
Sensitivity
(95 % CI)
Nose 26 (52 %) 27 (54 %) 0.89 (0.70–0.97)
Throat 21 (42 %) 27 (54 %) 0.78 (0.57–0.90)
Groin 31 (62 %) 34 (68 %) 0.88 (0.72–0.96)
Pooled results from separated analysis of the three sitesa 38 (76 %) 39 (78 %) 0.92 (0.78–0.98)
Pooled from three separated eSwabs by lab technicians 35 (70 %) 36 (72 %) 0.86 (0.70–0.95)
Swabs pooled within one eSwab tube by nurses 34 (68 %) 36 (72 %) 0.86 (0.70–0.95)
a If one or more sites were positive, the pooled result was considered to be positive. It was considered to be negative only when the three sites were
all negative
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that the limit of detection of enrichment culture was about
15 times lower (40 CFU/ml) than the Xpert MRSA PCR
(610 CFU/ml) [18].
In this work, we also observed 68 false-positive results.
Among these, 33 (49 %) were due to the presence of
methicillin-sensitive S. aureus strains that did not possess
the mecA gene, but still possessed part of the SCCmec gene
and the chromosome targeted by the Xpert MRSA test
(detected according to a previously described protocol
[22]). False-positive results could also be due to the pres-
ence of dead MRSA cells in former carriers.
In conclusion, the high NPV (99 %) of the Xpert MRSA
assay that we observed when pooling nose, throat, and groin
samples supports the use of this procedure to detect MRSA
and to rapidly stop or avoid unnecessary preemptive isola-
tion measures. By pooling these samples, we increased the
efficiency of MRSA screening without increasing the labo-
ratory costs. Moreover, by using the eSwab system, auto-
mated inoculation is possible.
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